Navigation Links
China Kangtai Cactus Biotech Retains Hawk Associates for Investor Relations Services
Date:7/6/2009

HARBIN, China, July 6 /PRNewswire-Asia-FirstCall/ -- China Kangtai Cactus Biotech Inc. (OTC Bulletin Board: CKGT), a vertically integrated grower, developer, manufacturer and marketer of cactus-based consumer products in China, announced today that it has retained the services of Hawk Associates for strategic investor relations. Information about China Kangtai will be available through the Hawk Associates website at: http://www.hawkassociates.com , featuring company updates, investor information and live financial feeds.

China Kangtai CEO Jinjiang Wang said, "We look forward to working with Hawk Associate, which has been providing comprehensive strategic IR services for 14 years in their roles as trusted advisors. We believe Hawk Associates is one of the premier investor relations firms that effectively helps companies successfully communicate their stories to the investment community. The branding and investor relations expertise that Hawk provides will be essential in assisting management in showcasing the true value of our company."

Hawk Associates CEO Frank Hawkins said, "As the dominant producer with 60% market share of China's edible cactus production, China Kangtai is a major beneficiary of growing Chinese demand for health and wellness products. In China, cactus products are traditionally used for treatment for health issues such as diabetes, adiposity, constipation, cholesterol, high blood pressure, low immunity and skin disorders. This is a unique company in an unsaturated industry. With the company's recent acquisition in March, Kangtai is seeking to increase its production capabilities in an effort to enhance its overall growth. We are thrilled to be able to help Kangtai tell its story to the investment community to strengthen its long-term valuation."

About China Kangtai Cactus Biotech, Inc.

China Kangtai Cactus Biotech Inc. is a leading grower, developer, producer and marketer of cactus-derived products, including nutraceuticals, nutritional food and drinks, and animal feed. China Kangtai controls over 387 acres of plants and maintains an active R&D group that holds 18 product patents and is seeking another 12 in a variety of product categories. China Kangtai's high-quality "green" products are sold throughout China in supermarkets, food stores, hotels and restaurants through a growing distribution network that has currently covered 12 provinces and 2 municipalities. For more information, please contact: Chengzhi Wang, General Manager of China Kangtai Cactus Biotech, Inc. Email: chinakangtai@gmail.com

For more investor-related questions, contact Susan Zhou, Hawk Associates, at 305-451-1888. To subscribe to future releases via e-mail alert, visit http://www.hawkassociates.com/about/alert/ .

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.


'/>"/>
SOURCE China Kangtai Cactus Biotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. RainEarth (RNER) Continues to Expand its Marketing Force in China
2. Sinovac Receives Chinas First Influenza A (H1N1) Vaccine Order
3. China-Biotics, Inc. to Join Russell 3000 Index
4. NeoStem Signs Agreement with Shanghai Corporation to Develop A Stem Cell Collection and Treatment Network in Shanghai, Taiwan and Other Targeted China Provinces
5. China Biologic Products Closes the $9.6 Million Private Placement
6. China Biologic Products Enters Into Private Placement Agreements to Raise $9.6 Million
7. Chinas Vice Premier, Li Keqiang, Visits Sinovac to Inspect H1N1 Vaccine Production Preparation
8. Gerresheimer Opens New High-Tech Production Facility for Pharma Glass in China
9. China-Biotics, Inc. to Attend Digestive Disease Week 2009
10. China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs
11. China Sky One Medical, Inc. Signs Agreement with Taiwan Golden Biotechnology Corp. on Development of New Anti-Cancer Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017  Applied BioMath ( www.appliedbiomath.com ... to drug research and development, today announced ... Inc. for quantitative systems pharmacology (QSP) support ... the treatment of cancer. ... GLP toxicology studies and first-in-human dose predictions ...
(Date:3/29/2017)... ... March 29, 2017 , ... ACEA Biosciences, ... disperses a quarterly travel award to noteworthy scientists who will be presenting research ... its new round of awards are being given to two postdoctoral fellows studying ...
(Date:3/29/2017)... 29, 2017 Research and Markets has announced ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... around 7.8% over the next decade to reach approximately $825.4 million ... estimates and forecasts for all the given segments on global as ...
(Date:3/29/2017)... , March 29, 2017 /PRNewswire/ -  GeneNews Limited ... BreastSentry™ , a new risk stratification test for breast ... lab, Innovative Diagnostics Laboratory ("IDL"). BreastSentry incorporates a blood-based biomarker ... and lifetime risk for developing breast cancer.   ... BreastSentry measures the ...
Breaking Biology Technology:
(Date:2/16/2017)... 2017  Genos, a community for personal genetic ... received Laboratory Accreditation from the College of American ... laboratories that meet stringent requirements around quality, accuracy ... "Genos is committed to maintaining the ... honored to be receiving CAP accreditation," said ...
(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
Breaking Biology News(10 mins):